Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition (Tables)

v3.23.1
Revenue Recognition (Tables)
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Contract Assets and Liabilities
The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):
March 31, 2023 December 31, 2022
Current pharma contract assets (1)
$ 1,121  $ 1,898 
Long-term pharma contract assets (2)
—  31 
Total pharma contract assets $ 1,121  $ 1,929 
Current pharma capitalized commissions (1)
$ 912  $ 800 
Long-term pharma capitalized commissions (2)
632  715 
Total pharma capitalized commissions $ 1,544  $ 1,515 
Current pharma contract liabilities $ 6,067  $ 7,557 
Long-term pharma contract liabilities (3)
—  19 
Total pharma contract liabilities $ 6,067  $ 7,576 

(1) Recorded within other current assets on the Consolidated Balance Sheets.
(2) Recorded within other assets on the Consolidated Balance Sheets.
(3) Recorded within other long-term liabilities on the Consolidated Balance Sheets.
Schedule of Disaggregation of Revenue
The following table details the disaggregation of revenue for both the Clinical Services and Pharma Services segments (in thousands):
Three Months Ended March 31,
2023 2022
Clinical Services:
    Client direct billing $ 76,823  $ 65,014 
    Commercial Insurance 21,355  18,288 
    Medicare and Medicaid 16,587  15,465 
    Self-Pay 104  24 
Total Clinical Services $ 114,869  $ 98,791 
Pharma Services 22,351  18,378 
Total Revenue $ 137,220  $ 117,169